FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023489093> ?p ?o ?g. }

• W2023489093 endingPage "1067" @default.
• W2023489093 startingPage "1059" @default.
• W2023489093 abstract "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas. The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide.Patients were stratified according to co-administration of enzyme-inducing anti-epileptic drugs (EIAEDs). There were 26 evaluable patients enrolled (16 on EIAEDs, 10 not on EIAEDs). All but seven patients had Glioblastoma Multiforme (GBM), and only six cases had a Karnosfsky Performance Status (KPS) of less than 80; median age was 51 years. All had received prior radiotherapy and 14 patients had no prior chemotherapy. The starting dose of temozolomide was 150 mg/m(2)/day for 5 days every 28 days and could be escalated to a maximum dose of 200 mg/m(2)/day in subsequent cycles. The starting dose of gefitinib was 500 mg/day given by mouth on a continuous basis. Dose-limiting toxicity was assessed in cycle one only.For patients on EIAEDs, the MTD of gefitinib was 1,000 mg/day in combination with temozolomide. Dose-limiting toxicity (DLT) was due to diarrhea, nausea and vomiting. For patients not on EIAEDs, the MTD was 250 mg/day in combination with temozolomide. The DLT was due to increases in liver transaminases. Rash was not a significant toxicity at these dose levels. The peak concentration and AUC(0-24hr) at the 500 mg dose level was 1.8 and 2.5-fold lower, respectively, in the EIAED group compared to the non-EIAED group; trough levels of gefitinib increased in both groups consistent with the reported terminal half-life ranging from 27 to 51 h.The recommended phase-2 dose of gefitinib when used in combination with temozolomide is 1,000 and 250 mg/day, respectively, for patients on or not on EIAEDs." @default.
• W2023489093 created "2016-06-24" @default.
• W2023489093 creator A5003825991 @default.
• W2023489093 creator A5015598221 @default.
• W2023489093 creator A5021656597 @default.
• W2023489093 creator A5034370633 @default.
• W2023489093 creator A5040044145 @default.
• W2023489093 creator A5046264008 @default.
• W2023489093 creator A5046338327 @default.
• W2023489093 creator A5051168746 @default.
• W2023489093 creator A5063511816 @default.
• W2023489093 creator A5075492015 @default.
• W2023489093 date "2007-08-11" @default.
• W2023489093 modified "2023-09-23" @default.
• W2023489093 title "Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study" @default.
• W2023489093 cites W2001133071 @default.
• W2023489093 cites W2002943210 @default.
• W2023489093 cites W2043696829 @default.
• W2023489093 cites W2045993433 @default.
• W2023489093 cites W2069907205 @default.
• W2023489093 cites W2070151637 @default.
• W2023489093 cites W2092108048 @default.
• W2023489093 cites W2096287682 @default.
• W2023489093 cites W2099708088 @default.
• W2023489093 cites W2115078677 @default.
• W2023489093 cites W2117941094 @default.
• W2023489093 cites W2123847172 @default.
• W2023489093 cites W2129160559 @default.
• W2023489093 cites W2137551916 @default.
• W2023489093 cites W2148345901 @default.
• W2023489093 cites W2154670277 @default.
• W2023489093 cites W2161821474 @default.
• W2023489093 cites W2162565810 @default.
• W2023489093 cites W2167690964 @default.
• W2023489093 doi "https://doi.org/10.1007/s00280-007-0556-y" @default.
• W2023489093 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3873156" @default.
• W2023489093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17694310" @default.
• W2023489093 hasPublicationYear "2007" @default.
• W2023489093 type Work @default.
• W2023489093 sameAs 2023489093 @default.
• W2023489093 citedByCount "46" @default.
• W2023489093 countsByYear W20234890932012 @default.
• W2023489093 countsByYear W20234890932013 @default.
• W2023489093 countsByYear W20234890932014 @default.
• W2023489093 countsByYear W20234890932015 @default.
• W2023489093 countsByYear W20234890932016 @default.
• W2023489093 countsByYear W20234890932017 @default.
• W2023489093 countsByYear W20234890932018 @default.
• W2023489093 countsByYear W20234890932019 @default.
• W2023489093 countsByYear W20234890932020 @default.
• W2023489093 countsByYear W20234890932021 @default.
• W2023489093 crossrefType "journal-article" @default.
• W2023489093 hasAuthorship W2023489093A5003825991 @default.
• W2023489093 hasAuthorship W2023489093A5015598221 @default.
• W2023489093 hasAuthorship W2023489093A5021656597 @default.
• W2023489093 hasAuthorship W2023489093A5034370633 @default.
• W2023489093 hasAuthorship W2023489093A5040044145 @default.
• W2023489093 hasAuthorship W2023489093A5046264008 @default.
• W2023489093 hasAuthorship W2023489093A5046338327 @default.
• W2023489093 hasAuthorship W2023489093A5051168746 @default.
• W2023489093 hasAuthorship W2023489093A5063511816 @default.
• W2023489093 hasAuthorship W2023489093A5075492015 @default.
• W2023489093 hasBestOaLocation W20234890932 @default.
• W2023489093 hasConcept C112705442 @default.
• W2023489093 hasConcept C121608353 @default.
• W2023489093 hasConcept C126322002 @default.
• W2023489093 hasConcept C2776694085 @default.
• W2023489093 hasConcept C2777389519 @default.
• W2023489093 hasConcept C2778227246 @default.
• W2023489093 hasConcept C2778570526 @default.
• W2023489093 hasConcept C2779438470 @default.
• W2023489093 hasConcept C2780580376 @default.
• W2023489093 hasConcept C2780580887 @default.
• W2023489093 hasConcept C2780852908 @default.
• W2023489093 hasConcept C29730261 @default.
• W2023489093 hasConcept C502942594 @default.
• W2023489093 hasConcept C71924100 @default.
• W2023489093 hasConcept C90924648 @default.
• W2023489093 hasConcept C98274493 @default.
• W2023489093 hasConceptScore W2023489093C112705442 @default.
• W2023489093 hasConceptScore W2023489093C121608353 @default.
• W2023489093 hasConceptScore W2023489093C126322002 @default.
• W2023489093 hasConceptScore W2023489093C2776694085 @default.
• W2023489093 hasConceptScore W2023489093C2777389519 @default.
• W2023489093 hasConceptScore W2023489093C2778227246 @default.
• W2023489093 hasConceptScore W2023489093C2778570526 @default.
• W2023489093 hasConceptScore W2023489093C2779438470 @default.
• W2023489093 hasConceptScore W2023489093C2780580376 @default.
• W2023489093 hasConceptScore W2023489093C2780580887 @default.
• W2023489093 hasConceptScore W2023489093C2780852908 @default.
• W2023489093 hasConceptScore W2023489093C29730261 @default.
• W2023489093 hasConceptScore W2023489093C502942594 @default.
• W2023489093 hasConceptScore W2023489093C71924100 @default.
• W2023489093 hasConceptScore W2023489093C90924648 @default.
• W2023489093 hasConceptScore W2023489093C98274493 @default.
• W2023489093 hasIssue "6" @default.
• W2023489093 hasLocation W20234890931 @default.
• W2023489093 hasLocation W20234890932 @default.

• next